INNOPRAN XL Rx
Generic Name and Formulations:
Propranolol HCl 80mg, 120mg; ext-rel caps.
Indications for INNOPRAN XL:
≥18yrs: Take once daily at bedtime (10PM). Take consistently with regard to food. Initially 80mg/day, may increase to 120mg/day.
<18yrs: not recommended.
Cardiogenic shock. Sinus bradycardia, sick sinus syndrome and >1st -degree AV block unless paced. Asthma.
Risk of cardiac ischemia after abrupt discontinuation. Bronchospastic disease. Heart failure. Cardiogenic shock. Wolff-Parkinson-White syndrome. Diabetes. May mask signs of hypoglycemia, hyperthyroidism. Surgery. SLE. Musculoskeletal disease. Renal or hepatic impairment. Avoid abrupt cessation. Elderly. Pregnancy (Cat.C). Nursing mothers.
Potentiated by substrates or inhibitors of CYP2D6 (eg, amiodarone, cimetidine, fluoxetine, paroxetine, quinidine, ritonavir), CYP1A2 (eg, imipramine, ciprofloxacin, theophylline, zolmitriptan), or CYP2C19 (eg, fluconazole), CNS depressants, other antihypertensives, antithyroid drugs, haloperidol, MAOIs, tricyclic antidepressants, alcohol. Antagonized by NSAIDs, aluminum hydroxide; bile acid resins (eg, cholestyramine, colestipol); smoking, chronic alcohol use, and other inducers of CYP2D6, 1A2, or 2C19. Potentiates amiodarone, chlorpromazine, diazepam, lidocaine, bupivacaine, mepivacaine, propafenone, theophylline, thioridazine, warfarin, rizatriptan, zolmitriptan. May increase cardiac effects of calcium channel blockers, digitalis, disopyramide, lidocaine. Bradycardia with catecholamine-depleting drugs. Increased orthostatic hypotension with α-blockers. Caution when withdrawing clonidine. Increased bronchial hyperreactivity with ACEIs. May interfere with glaucoma or thyroid tests. May block epinephrine.
Fatigue, dizziness, constipation, bradycardia, heart failure/block, GI upset, bronchospasm, agranulocytosis, myopathy, myotonia, skin reactions (eg, rash, Stevens-Johnson syndrome, urticaria); rare: SLE, alopecia, impotence.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|